- Information Center
- Investment News
According to Yonhap News,
(SEOUL=Yonhap News) The Global Bio Conference 2016 (GBC 2016) is taking place at the InterContinental Seoul COEX, Korea from June 27th to July 1st, 2016 hosted by the Ministry of Food and Drug Safety (MFDS) and organized by Korea Biomedicine Industry Association.
The conference is held to foster the biopharmaceutical industry as a new growth engine and promote global business expansion of local biopharmaceutical companies amid growing importance of biopharmaceutical industry. Experts from regulatory authorities, international organizations, academic institutes, industry, and research centers will gather at the international event.
"As the biopharmaceutical industry is emerging as a new growth industry, Korea is working hard to become the world's seventh powerful country in the bio and healthcare sector," the Prime Minister Hwang Kyo-ahn said in a video message. He added that "the government aims to develop the bio industry by expanding R&D investment, fostering experts, and increasing tax benefit."
"Korea already secured the world-class technological expertise and competitiveness as proven by the world's first development of antibody bio-similar and stem cell medicine. The government will do its utmost effort to nurture the biopharmaceutical industry so that it grows to the nation's core industry," the minister of MFDS Sohn Mungi said.
Over 2,000 experts including 50 overseas biopharmaceutical regulators, government officials, industry and academic leaders are invited to discuss new paradigm of the healthcare industry and share their experience and knowledge.
On the sidelines of the conference, invited lectures, biopharmaceutical forum and international meeting, and events to promote export of locally-developed pharmaceutical products are scheduled to take place.
Local pharmaceutical companies can meet regulators from their target export market to have customized consultations for expanding their business globally. The consultation session will be attended by regulators from 10 countries including the Czech Republic, Poland, Brazil, and Saudi Arabia.
At the biopharmaceutical international meeting held jointly by MFDS and WHO during the same period, recent development of newly spreading infectious diseases including Middle East Respiratory Syndrome (MERS) and Zika virus will be reviewed and national-level strategies in epidemics control will be discussed.
Copyrights Yonhap News. All Rights Reserved.
Source: Yonhap News (Jun. 27, 2016)
** This article is translated from the Korean.